Breaking News! Eli Lilly’s Oral GLP-1 Weight-loss Drug Orforglipron Gains FDA Accelerated Approval

News dated April 1, 2026: The U.S. FDA officially approved the launch of Eli Lilly’s Orforglipron under the brand name Foundayo. It is the II orally administered GLP-1 weight-loss drug approved worldwide, marking that the global weight management market is officially stepping into a new oral-dominated era from the injection-dominated era.

With the steadily rising number of diabetic and obese patients across the globe, Orforglipron stands out as a revolutionary oral medication. Differing from traditional injectable medicines, it is an oral non-peptide small-molecule drug that greatly improves medication convenience for patients. Since Orforglipron entered the commercialization phase on April 1, 2026, the R&D and industrial production of its core intermediates have drawn wide attention in the industry.

This approval is of milestone significance for the Chinese market. Up to now, Orforglipron is the only oral GLP-1 weight loss drug that has submitted marketing applications for obesity and overweight indications in China, and is highly likely to become the first approved oral GLP-1 weight loss drug in China.

The landscape of the hundred-billion-level weight loss pharmaceutical track is poised to be completely reshaped by this oral drug.

Orforglipron

Orforglipron Starting Materials and Intermediates

RELYBO is committed to providing global customers with high-purity, high-quality Orforglipron intermediates with stable supply from kilogram to ton cales, accelerating the innovation and commercialization.